USP18 and hairy cell leukemia: Alternatively, USP18 antagonists or strategies promoting USP18 degradation could promote the beneficial effect of therapeutic IFNs used in multiple sclerosis, hairy cell leukemia, and melanoma (Meuwissen et al., 2016).